The butterfly lives on until February 2014 and could get an additional 6 months down the road, pending pediatric study results. A while back I posted a spoof on the product from Saturday Night Live and you can view here, no wonder they don’t need to spend much on advertising. BD
Sepracor Inc. today announced that the United States Patent and Trademark Office has determined that U.S. Patent No. 6,444,673, which is a composition of matter patent that covers the human drug product LUNESTA® (eszopiclone), received a patent term extension under 35 U.S.C. § 156. The period of extension was determined to be 760 days, and the new expiration date of the patent is February 14, 2014. LUNESTA is marketed by Sepracor for the treatment of insomnia. In addition, the exclusivity period could potentially be extended for an additional six months if Sepracor successfully obtains a pediatric exclusivity extension by submitting data developed in accordance with the pediatric Written Request.
Sepracor's LUNESTA receives patent term extension from USPTO
Technorati Tags: Sepracor, Lunesta, patent, FDA, heatlhcare, United States Patent and Trademark Office, pediatrics
0 comments :
Post a Comment